Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Celltrion (068270) – Notice of Ex-Dividend Reference Price / 2024-12-26

Posted on December 26, 2024August 6, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) – Notice of Ex-Dividend Reference Price / 2024-12-26

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

The Korea Exchange set and announced the ex-dividend reference price for Celltrion’s common shares at KRW 182,900, effective December 27, 2024, to reflect its stock dividend.

📊 Key Disclosure Content & Financial Highlights

  1. Overview
  • Company: Celltrion, Inc. (Stock Code: 068270)
  • Disclosure Type: Notice of Ex-Dividend Reference Price
  • Effective Date: December 27, 2024
  1. Security Details & Reference Price
  • Share Class: Common Share
  • Ex-Dividend Reference Price: KRW 182,900
  • Reason: Adjustments due to stock dividend declaration
  • Governing Regulation: Article 30 of the Enforcement Rules of the KOSPI Market Operational Regulations

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Ex-Dividend Reference Price Implementation

This disclosure serves as official notification regarding the ex-dividend reference price applied to Celltrion common shares starting December 27, 2024, following its stock dividend. Verifying that the opening stock price on the ex-dividend date reflects the adjusted reference price (KRW 182,900) is important for monitoring market valuation and position baseline. Relevant updates can be confirmed through KRX market data and future periodic filings.

📢 Disclaimer & Source Notice

Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.

Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] ALTEOGEN (196170) – Results of Extraordinary General Shareholders Meeting / 2024-12-26
Next Post: [Disclosure] Hanwha Systems (272210) Amends DAPA Contract: ‘TICN 4th Mass Production’ Value Increased to KRW 612.2B, Completion Date Extended

Related Posts

[Disclosure] Samsung Biologics (207940) – Provisional Operating Results Based on Consolidated Financial Statements (Fair Disclosure) / 2025-01-22 Disclosures
[Disclosure] SK Square (402340) – (Correction) Decision on Paid-in Capital Increase / 2026-07-06 Semiconductors
[Disclosure] Samsung Electro-Mechanics (009150) – Advance Notice of Earnings Release / 2026-07-09 Semiconductors
[Disclosure] Hanwha Systems (272210) Australian Subsidiary HAA No.1 Decides to Acquire 9.91% Stake (KRW 168.7B) in Shipbuilder Austal Disclosures
[Disclosure] Hanwha Systems (272210) – Corrected Filing for Subsidiary HS USA Holdings Corp. Capital Increase (Payment Date Revised to Dec 22, 2025) Disclosures
[Disclosure] Hanwha Aerospace (012450) to Hold Investor Relations (IR) Meetings for Major Overseas Institutional Investors in Hong Kong and Singapore Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme